Intellect Neurosciences (ILNS.OB) Completes Financial Restructuring, Highlights Expectations for Alzheimer’s Drug
Intellect Neurosciences Inc. engages in the discovery and development of disease-modifying therapeutic agents for Alzheimer’s disease (AD). The company recently restructured its balance sheet and today announced that through the issuance of common stock, it was successful in extinguishing about $24 million of accrued interest of debt and preferred stock. In addition, the company said that several of its “significant” shareholders pooled together to provide enough funds fuel the company’s operations for the next 12 months. Company chairman and CEO Daniel Chain, PhD, said the funding enables the company to pursue new opportunities for its drug development. "Our stakeholders recognize…